Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Unitaid
Deal Size : $6.0 million
Deal Type : Funding
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
Details : The mdc-STM is an investigational three-month active injectable formulation of ivermectin using Medincell’s BEPO technology to fight malaria transmission.
Brand Name : mdc-STM
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 08, 2024
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Unitaid
Deal Size : $6.0 million
Deal Type : Funding
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The SAIVE study was conducted to support mdc-TTG program, whose objective is to provide prevention of Covid-19 infection for weeks or months with a single injection of a long-acting formulation of ivermectin based on MedinCell’s proprietary technology,...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 05, 2023
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : The Medicines Patent Pool
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : This non-exclusive licence agreement, will enable MPP to support the identification of suitable partners for the development and commercialisation of mdc-STM, an injectable formulation of ivermectin with a three-month action-duration.
Brand Name : mdc-STM
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 13, 2022
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : The Medicines Patent Pool
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ivermectin
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zydus Gets USFDA Nod for Ivermectin Cream
Details : Ivermectin is a Food and Drug Administration (FDA)-approved antiparasitic drug used to treat several neglected tropical diseases, including onchocerciasis, helminthiases, and scabies.
Brand Name : Ivermectin-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 04, 2022
Lead Product(s) : Ivermectin
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lyndra’s investigational long-acting oral biweekly ivermectin (LYN-163), enabled by Lyndra’s LYNX™ drug delivery platform, is being studied as a tool in the fight to eradicate malaria.
Brand Name : LYN-163
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 09, 2022
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MedinCell: Inclusion of First Participants in New Covid-19 Prophylaxis Clinical Trial SAIVE
Details : The objective of MedinCell’s mdc-TTG program is to protect humans from Covid-19 and its variants with a long-acting injection of Ivermectin, SAIVE aims at validating the efficacy in prophylaxis against Covid-19 of administration of Ivermectin in oral d...
Brand Name : mdc-TTG
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 28, 2022
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ivermectin is FDA-approved for prescription use in humans as an antiparasitic drug to treat conditions including intestinal strongyloidiasis and onchocerciasis or river blindness.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 20, 2021
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MedinCell’s Long-Acting Injectable to Fight Malaria Ready to Enter Regulatory Development
Details : The investigational product mdc-STM aims at reducing the transmission of the parasite responsible for Malaria, thanks to a killing effect on the vector mosquitoes when they bite treated people.
Brand Name : mdc-STM
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 14, 2021
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A single dose of 2.5 milligrams per kilogram of Ivectosol™ was effective at interfering with viral replication and driving viral clearance of the B.1.1.7 COVID-19 variant.
Brand Name : Ivectosol
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 18, 2021
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Clinical Trial Conducted by MedinCell Confirms the Safety of Continuous Administration of Ivermectin
Details : Ivermectin has already been administered as a once-daily treatment to hundreds of millions of patients worldwide. Its safety as a once-daily treatment has been demonstrated and documented.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 19, 2021
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?